Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

OBJECTIVE: We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine whether there was persistence of effect. RESEARCH DESIGN...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Orban, Tihamer, Bundy, Brian, Becker, Dorothy J., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Greenbaum, Carla J., Marks, Jennifer B., Monzavi, Roshanak, Moran, Antoinette, Peakman, Mark, Raskin, Philip, Russell, William E., Schatz, Desmond, Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Diabetes Association 2014
Schlagworte:
Emerging Technologies and Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964491/
https://ncbi.nlm.nih.gov/pubmed/24296850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc13-0604
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge